Marimastat treatment significantly reduced proinflammatory cytokines (Il‐1β and Il‐6), ER stress markers (CHOP and Grp78), and tumor markers (CD31 and AFP) (Fig. 7A). The gene discussed is IL1B; the disease is neoplasm.